Session » Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II (1565–1583)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1570

AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study

8:30AM-10:30AM: Abstract Number: 1568

AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment

8:30AM-10:30AM: Abstract Number: 1565

Causal Mediation Analysis of the Relationship of Canakinumab’s Protective Effect Against Gout Flares and High-sensitivity C-reactive Protein in the CANTOS Trial

8:30AM-10:30AM: Abstract Number: 1574

Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography

8:30AM-10:30AM: Abstract Number: 1583

Creation of an Ultrasonographic Scoring System for CPPD Extent: Results from a Delphi Process by the OMERACT US Working Group – CPPD Subgroup

8:30AM-10:30AM: Abstract Number: 1576

Development of a Plain Radiographic Scoring System for New Bone Formation in Gout

8:30AM-10:30AM: Abstract Number: 1582

Diagnostic Accuracy and Reliability of Conventional Radiography of the Knee in Calcium Pyrophosphate Deposition Disease by Using New Definitions: An Ancillary Study of the OMERACT Ultrasound – CPPD Group

8:30AM-10:30AM: Abstract Number: 1569

Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation

8:30AM-10:30AM: Abstract Number: 1571

Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout

8:30AM-10:30AM: Abstract Number: 1581

Genetic Effects on the Transition from Hyperuricemia to Gout

8:30AM-10:30AM: Abstract Number: 1566

Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery

8:30AM-10:30AM: Abstract Number: 1577

Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout

8:30AM-10:30AM: Abstract Number: 1578

NLRP3 Inflammasome Pathway Expression at Atheroma Plaques from Peripheral Artery Disease According to the Uricemic Status

8:30AM-10:30AM: Abstract Number: 1567

Pharmacokinetics and Pharmacodynamics of Anthocyanins After Oral Administration of Oral Tart Cherry Juice Concentrate to Gout Patients

8:30AM-10:30AM: Abstract Number: 1579

Phenome-Wide Association of Gout Risk Loci

8:30AM-10:30AM: Abstract Number: 1572

Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia

8:30AM-10:30AM: Abstract Number: 1575

Urate Crystals Regulate a Distinct JNK-Dependent Metabolic and Inflammatory Response

8:30AM-10:30AM: Abstract Number: 1573

Vascular Monosodium Urate Crystal Deposition in Gout: A Dual-energy CT and Microscopy Study of Cadaveric Donors

8:30AM-10:30AM: Abstract Number: 1580

Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].